Navigation Links
Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
Date:2/12/2008

ose in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by a number of other factors, including the risk factors listed from time to time in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended April 30, 2007 and the quarterly report on Form 10-Q for the quarter ended October 31, 2007. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Peregrine Pharmaceuticals, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.

Contacts:

GendeLLindheim BioCom Partners

Investors Media

info@peregrineinc.com Jennifer Anderson

(800) 987-8256 (212) 918-4642


'/>"/>
SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
2. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
3. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
4. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
5. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
6. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
7. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
8. Access Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
9. XTL Biopharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
10. Koronis Pharmaceuticals Appoints David Drajeske Director of Business Development
11. Onyx Pharmaceuticals to Present at BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/18/2014)... October 19, 2014 The “Human ... Acting, Intermediate Acting, Premixed), Modern Human Insulin (Rapid ... Levemir, NovoRapid, Novomix, Tresiba, Others) - Forecast to ... drivers, restraints, challenges, opportunities, current market trends, and ... with the estimates and forecasts of the revenue ...
(Date:10/18/2014)... October 18, 2014 The Asia-Pacific hardware ... market in Asia-Pacific with analysis and forecast of revenue. ... is expected to reach $51,362.6 million by 2018, at ... Browse through the TOC of the Asia-Pacific hardware encryption ... analysis provided. This also provides a glimpse of the ...
(Date:10/18/2014)... According to a new market research report ... Global Trends & Forecasts up till 2017”, hydraulic fracturing ... This value is expected to increase from $40 billion ... CAGR during the same period. North America is expected ... terms of hydraulic horse power supplied by the year ...
(Date:10/17/2014)... Oct. 16—As in Alice,s journey through the looking-glass to ... in surprising and unexpected ways, including a new class ... As reported today in The Optical Society,s (OSA) new ... demonstrated, for the first time, a new type of ... instead reflects infrared light by using an unusual magnetic ...
Breaking Biology Technology:Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 2Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 3Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 4Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 5The Asia-Pacific hardware encryption display market is expected to reach $51,362.6 million by 2018 - New Report by MicroMarket Monitor 2The Asia-Pacific hardware encryption display market is expected to reach $51,362.6 million by 2018 - New Report by MicroMarket Monitor 3Hydraulic Fracturing Market Projected To Reach $64 Billion by 2017 - New Report by MarketsandMarkets 2Hydraulic Fracturing Market Projected To Reach $64 Billion by 2017 - New Report by MarketsandMarkets 3Hydraulic Fracturing Market Projected To Reach $64 Billion by 2017 - New Report by MarketsandMarkets 4Magnetic mirrors enable new technologies by reflecting light in uncanny ways 2Magnetic mirrors enable new technologies by reflecting light in uncanny ways 3Magnetic mirrors enable new technologies by reflecting light in uncanny ways 4
... ... PDSS Leadership Award at the 3rd Annual Pacific Drug Safety Summit, which took place last ... the moderator of the event and serves as Chairman of BioSoteria,s Board of Advisors. ... Emeryville, CA (PRWEB) September 30, ...
... TOKYO, September 30 Sosei Group Corporation,("Sosei"; TSE ... of the New Drug Application (NDA) for the emergency,contraceptive ... (MHLW) by Sosei Co. Ltd., its wholly owned Japanese ... oral emergency contraceptive "morning after pill" which,is used to ...
... N.C., Sept. 29 Oxygen Biotherapeutics, Inc. (OTC ... presentation for investors by company chairman and CEO, ... website. The link to the presentation can be ... Relations section of the website at www.oxybiomed.com. It ...
Cached Biology Technology:Hugh Tilson Receives Leadership Award at Pacific Drug Safety Summit 2Hugh Tilson Receives Leadership Award at Pacific Drug Safety Summit 3
(Date:10/14/2014)... 14, 2014 – Scientists from The Scripps Research Institute ... Institutes of Health (NIH) to lead an investigation of ... disease in Africa. The study aims to understand how ... die, while others survive the inflection. , "The ... mechanism of how Lassa fever virus causes disease and ...
(Date:10/14/2014)... week, an international team of researchers, led by the ... the journal Nature Genetics a brief genomic ... varieties of the tomato plant. , The C.M. Rick ... important role in this study by providing seed of ... This study, which builds on the first tomato genome ...
(Date:10/14/2014)... Philadelphia, PA, October 14, 2014 – Over the past ... failure of institutions to meet the needs of infants ... failure of these infants to thrive. , ... the development of the cortex. A generation of research ... explore, promote cortical development and cognitive function. In contrast, ...
Breaking Biology News(10 mins):Scripps Research Institute team receives $6.6 million to investigate deadly Lassa virus 2Institutional rearing may increase risk attention-deficit disorder 2
... -- Can,t help molding some snow into a ball and ... lake as you can? New research from Indiana University and ... species on Earth, readily learn to throw long distances. This ... with language development in a way critical to our very ...
... discovered the last major element of the series of chemical ... from a protein on the surface of a plant cell ... were already known, new research from a team including Carnegie,s ... about the mechanism through which brassinosteroids cause plant genes to ...
... COLUMBIA, Mo. In an article in the Nov. ... National Academy of Science , researchers with Dow AgroSciences and ... when transformed into corn and soybeans, provide robust resistance to ... and soybean growers a solution to the growing problem of ...
Cached Biology News:IU study: Humans' critical ability to throw long distances aided by an illusion 2IU study: Humans' critical ability to throw long distances aided by an illusion 3Nailing down a crucial plant signaling system 22 bacterial enzymes confer resistanceto common herbicide, say MU researchers 2
Chicken polyclonal to QPRT ( Abpromise for all tested applications). Antigen: Synthetic peptide, corresponding to Internal sequence amino acids 123-237 of Human QPRT Entrez Gene ID: 23475 ...
Antibody Diluent for IHC 125 ml...
QPRT Antibody...
Mouse monoclonal [4C4] to Y14 ( Abpromise for all tested applications). entrezGeneID: 9939 SwissProtID: Q9Y5S9...
Biology Products: